Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study

BACKGROUND: Currently there is no standard therapy recommended for second‐line treatment for thymic carcinoma. Our study compared multidrug chemotherapy, single‐agent chemotherapy, and PD‐1 inhibitors in patients diagnosed with advanced thymic carcinoma who had previous platinum‐based chemotherapy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yang, Zhang, Xuanye, Tian, Dan, Han, Sen, Zhang, Jie, Nie, Jun, Dai, Ling, Hu, Weiheng, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Wu, Di, Zhang, Ziran, Long, Jieran, Fang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939196/
https://www.ncbi.nlm.nih.gov/pubmed/35924403
http://dx.doi.org/10.1002/cam4.5053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939196/
https://www.ncbi.nlm.nih.gov/pubmed/35924403
http://dx.doi.org/10.1002/cam4.5053

Ejemplares similares